RxDoctor Payments Data

Bashir Al Kaddoumi

Interventional Cardiology · Houston, TXNPI 1194996702

Payments from drug & device makers

$19,590in general payments, 2019–2025

Across 183 payments — averaging $107.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$14K
  • Boston Scientific$1K
  • Inari Medical, Inc.$948
  • Biotronik Inc.$738
  • Amgen$549
  • Abbott$407
  • plus $2K from 23 others

What the payments were for

  • Speaking & faculty fees$13,80070%
  • Travel & lodging$1,5198%
  • Food & beverage$4,12821%
  • Education$1421%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,590 in reported general payments places this provider in the 65th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$324,314
Medicare patients
520
Services billed
2,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban195$199,259
XareltoRivaroxaban89$110,574
BrilintaTicagrelor93$76,830
EntrestoSacubitril/Valsartan25$22,336
FarxigaDapagliflozin Propanediol15$14,953
Repatha SyringeEvolocumab17$13,821
Repatha SureclickEvolocumab12$10,567
Prasugrel Hcl17$3,918
Metoprolol Succinate293$3,550
Atorvastatin Calcium310$2,748
Rosuvastatin Calcium171$2,477
ClopidogrelClopidogrel Bisulfate258$2,422
Dabigatran EtexilateDabigatran Etexilate Mesylate20$2,316
Losartan Potassium187$1,997
Nifedipine ErNifedipine76$1,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$199,259195 claims
Johnson & JohnsonXarelto$14,103$110,57489 claims
AstraZenecaBrilinta, Farxiga$247$91,784108 claims
NovartisEntresto$143$22,33625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →